News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Holding AG’s (JOBS) MabThera Meets Goal in Leukaemia Study
October 7, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 7 (Reuters) - Roche Holding AG's top-selling cancer drug MabThera delayed disease progression in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, or CLL, in a late-stage study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
·
3 min read
·
Annalee Armstrong
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 12, 2026
·
1 min read
·
Gabrielle Masson
Psychedelics
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout
August 12, 2026
·
4 min read
·
Gabrielle Masson
